EMAS clinical guide: selective estrogen receptor modulators for postmenopausal osteoporosis

Santiago Palacios; Mark Brincat; C Tamer Erel; Marco Gambacciani; Irene Lambrinoudaki; Mette H Moen; Karin Schenck-Gustafsson; Florence Tremollieres; Svetlana Vujovic; Margaret Rees; Serge Rozenberg

doi:10.1016/j.maturitas.2011.11.010

EMAS clinical guide: selective estrogen receptor modulators for postmenopausal osteoporosis

Maturitas. 2012 Feb;71(2):194-8. doi: 10.1016/j.maturitas.2011.11.010. Epub 2011 Dec 15.

Authors

Santiago Palacios¹, Mark Brincat, C Tamer Erel, Marco Gambacciani, Irene Lambrinoudaki, Mette H Moen, Karin Schenck-Gustafsson, Florence Tremollieres, Svetlana Vujovic, Margaret Rees, Serge Rozenberg

Affiliation

¹ Palacios Institute of Woman's Health Antonio Acuna, Madrid, Spain. [email protected]

PMID: 22176952
DOI: 10.1016/j.maturitas.2011.11.010

Abstract

Osteoporosis and the resulting fractures are major public health issues as the world population is ageing. Various therapies such as bisphosphonates, strontium ranelate and more recently denosumab are available. This clinical guide provides the evidence for the clinical use of selective estrogen modulators (SERMs) in the management of osteoporosis in postmenopausal women.

Publication types

Review

MeSH terms

Antibodies, Monoclonal / therapeutic use
Antibodies, Monoclonal, Humanized
Bone Density Conservation Agents / therapeutic use*
Denosumab
Diphosphonates / therapeutic use
Female
Fractures, Bone / prevention & control*
Humans
Organometallic Compounds / therapeutic use
Osteoporosis, Postmenopausal / drug therapy*
Selective Estrogen Receptor Modulators / therapeutic use*
Thiophenes / therapeutic use

Substances

Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Bone Density Conservation Agents
Diphosphonates
Organometallic Compounds
Selective Estrogen Receptor Modulators
Thiophenes
strontium ranelate
Denosumab